` ENLV (Enlivex Therapeutics Ltd) vs S&P 500 Comparison - Alpha Spread

ENLV
vs
S&P 500

Over the past 12 months, ENLV has underperformed S&P 500, delivering a return of -33% compared to the S&P 500's +15% growth.

Stocks Performance
ENLV vs S&P 500

Loading
ENLV
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
ENLV vs S&P 500

Performance Gap Between ENLV and GSPC
HIDDEN
Show

Performance By Year
ENLV vs S&P 500

Loading
ENLV
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Enlivex Therapeutics Ltd vs Peers

S&P 500
ENLV
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Enlivex Therapeutics Ltd
Glance View

Market Cap
20.3m USD
Industry
Biotechnology

Enlivex Therapeutics Ltd. develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.

ENLV Intrinsic Value
HIDDEN
Show
Back to Top